{"id":2506,"date":"2020-12-02T12:51:16","date_gmt":"2020-12-02T20:51:16","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=2506"},"modified":"2020-12-03T12:52:10","modified_gmt":"2020-12-03T20:52:10","slug":"repurposed-antiviral-drugs-for-covid-19-interim-who-solidarity-trial-results-2","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/12\/02\/repurposed-antiviral-drugs-for-covid-19-interim-who-solidarity-trial-results-2\/","title":{"rendered":"Repurposed Antiviral Drugs for Covid-19 \u2014 Interim WHO Solidarity Trial Results"},"content":{"rendered":"<p>In a randomized trial of 11,330 adult inpatients with COVID-19 from 30 countries, with 2750 assigned to remdesivir, 954 to hydroxychloroquine, 1411 to lopinavir (without interferon), 2063 to interferon (including 651 to interferon plus lopinavir), and 4088 to no trial drug, all trial drugs had little or no effect on overall mortality, initiation of ventilation, and duration of hospital stay. [<i>EDITORIAL NOTE: This manuscript was previously summarized as a pre-print on Oct 16].<\/i><\/p>\n<p><i>WHO Solidarity Trial Consortium (Dec 2, 2020). Repurposed Antiviral Drugs for Covid-19 \u2014 Interim WHO Solidarity Trial Results. The New England Journal of Medicine.<span class=\"Apple-converted-space\">\u00a0<\/span><\/i><\/p>\n<p><a href=\"https:\/\/doi.org10.1056\/NEJMoa2023184\">https:\/\/doi.org10.1056\/NEJMoa2023184<\/a><span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In a randomized trial of 11,330 adult inpatients with COVID-19 from 30 countries, with 2750 assigned to remdesivir, 954 to hydroxychloroquine, 1411 to lopinavir (without interferon), 2063 to interferon (including 651 to interferon plus lopinavir), and 4088 to no trial drug, all trial drugs had little or no effect on overall mortality, initiation of ventilation,&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/12\/02\/repurposed-antiviral-drugs-for-covid-19-interim-who-solidarity-trial-results-2\/\">Read more<\/a><\/div>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[28],"topic":[19],"class_list":["post-2506","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-treatment","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/2506","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=2506"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/2506\/revisions"}],"predecessor-version":[{"id":2507,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/2506\/revisions\/2507"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=2506"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=2506"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=2506"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=2506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}